Submitted by Anonymous (not verified) on 12 June 2025 - 15:10
Human medicines European public assessment report (EPAR): Rybrevant, amivantamab, Date of authorisation: 09/12/2021, Revision: 7, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Rybrevant, amivantamab, Date of authorisation: 09/12/2021, Revision: 7, Status: Authorised